API Shortage Hits Gujarat Drug Manufacturers, Industry Warns of Production Delays

The Times of India has highlighted a growing shortage of active pharmaceutical ingredients (APIs) that is affecting drug manufacturers in Gujarat. Industry sources say the scarcity is disrupting the supply chain and could delay the production of several medicines that the state’s firms supply domestically and abroad.

Analysts note that Gujarat, home to a large share of India’s pharmaceutical output, relies heavily on imported APIs. Any disruption in global availability therefore reverberates quickly across local factories, forcing some to scale back batches or seek alternative suppliers.

The situation has prompted calls for greater inventory buffers and accelerated efforts to boost domestic API manufacturing. While officials have not disclosed specific impact figures, the shortage underscores the sector’s vulnerability to external supply shocks.

Stakeholders are monitoring the issue closely, as prolonged constraints could affect drug availability and export commitments. The industry is urging the government to facilitate faster approvals for new API production units to mitigate future shortages.